FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of March, 2006
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosure:
1. Notice of Results
2. Director/PDMR Shareholding
3. Director/PDMR Shareholding
Notice of results
Cambridge, UK and Cambridge, Massachusetts - 28 February 2006 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) will announce its preliminary results for
the year ended 31 December 2005 on Thursday, 9 March 2006.
The results announcement will be released at 7.00 am GMT. An analyst briefing
will be held at 9.00 am GMT at The Brewery, Chiswell Street, London EC1 and will
also be accessible via a conference call. For details, contact Mo Noonan at
Financial Dynamics on +44 (0) 20 7269 7116. An instant replay of the call will
be available until Thursday, 16 March 2006 on telephone numbers UK: +44 (0) 20
7365 8427 and US: + 1 (617) 801 6888. The pin code is 38146945.
An audio webcast of the call will also be available via Acambis' website at
www.acambis.com. The webcast replay will be available until 16 March 2006.
-ends-
Enquiries:
Acambis plc
Lyndsay Wright,
VP Communications and Investor Relations: Tel +44 (0) 1223 275 300
Financial Dynamics
Mo Noonan: Tel +44 (0) 20 7269 7116
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis' US-based subsidiary Berna Products
Corporation markets Vivotif(R), the world's only licensed oral typhoid vaccine,
in North America. Acambis' investigational vaccine against Japanese
encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has
the most advanced investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last six years, and a vaccine against Clostridium
difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2004 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Increase in Directors' shareholdings
Cambridge, UK - 27 March 2006 - Acambis plc ("Acambis") (LSE: ACM, NASDAQ: ACAM)
announces a number of transactions which took place on 24 March 2006 involving
Directors' shareholdings in Acambis.
David Lawrence, Chief Financial Officer, purchased a total of 7,500 shares at
196.5p per share for himself and on behalf of certain family members. After this
transaction, the shareholding in Acambis held by Mr Lawrence and on behalf of
his family (being connected persons) was 8,300 shares, representing
approximately 0.01% of Acambis' issued share capital.
Dr Peter Fellner, Non-executive Director, purchased 14,000 shares at 196.5p per
share. After this transaction, the shareholding in Acambis held by Dr Fellner
was 14,000 shares, representing approximately 0.01% of Acambis' issued share
capital.
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary Tel: +44 (0) 1223 275 300
Lyndsay Wright,
VP, Communications and Investor Relations
-ends-
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis' US-based subsidiary Berna Products
Corporation markets Vivotif(R), the world's only licensed oral typhoid vaccine,
in North America. Acambis' investigational vaccine against Japanese
encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has
the most advanced investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last six years, and a vaccine against Clostridium
difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2004 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Directors' interests in shares
Cambridge, UK - 28 March 2006 - Acambis plc ("Acambis") (LSE: ACM, NASDAQ: ACAM)
announces that, on 27 March 2006, the following grants of options under the
Acambis 1999 Share Option Scheme and awards under the Acambis Long-term
Incentive Plan ("LTIP") were made to the three Executive Directors:
Total shares over which
Director Share options LTIPs options held (note 1)
Gordon Cameron 183,502 91,751 1,006,235
David Lawrence 100,000 50,000 448,630
Dr Thomas Monath 99,925 49,962 593,466
Both the share options and LTIPs were granted over ordinary 10p shares. The
share options were granted at exercise price of 197p per share. On exercise of
the LTIP awards, a nominal GBP1.00 would be payable by each Director. The
exercise periods applicable are 27 March 2009 to 26 March 2016 and 27 March 2009
to 26 September 2009 for the options and LTIPs respectively. No amount was
payable by the Directors on the grant of these share options or LTIPs.
Note 1: The total shares over which options are held (share options and LTIPs)
following all of the above transactions detailed within this news
release.
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations
-ends-
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis' US-based subsidiary Berna Products
Corporation markets Vivotif(R), the world's only licensed oral typhoid vaccine,
in North America. Acambis' investigational vaccine against Japanese
encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. It also has
the most advanced investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last six years, and a vaccine against Clostridium
difficile bacteria, a leading cause of hospital-acquired infections.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2004 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 31 March, 2006 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: VP, Communications and IR.